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HENa, heterogeneous network-
based data set for alzheimer’s 
disease
Elena Sügis1,2, Jerome Dauvillier3, anna Leontjeva4, Priit adler1,2, Valerie Hindie5, 
thomas Moncion5, Vincent Collura5, Rachel Daudin6,7, Yann Loe-Mie8, Yann Herault  9, 
Jean-Charles Lambert  10, Henning Hermjakob  11, tal Pupko12, Jean-Christophe Rain5, 
Ioannis Xenarios13,14,15,16, Jaak Vilo1,2, Michel Simonneau6,7 & Hedi Peterson  1,2
alzheimer’s disease and other types of dementia are the top cause for disabilities in later life and various 
types of experiments have been performed to understand the underlying mechanisms of the disease 
with the aim of coming up with potential drug targets. these experiments have been carried out by 
scientists working in different domains such as proteomics, molecular biology, clinical diagnostics and 
genomics. the results of such experiments are stored in the databases designed for collecting data of 
similar types. However, in order to get a systematic view of the disease from these independent but 
complementary data sets, it is necessary to combine them. In this study we describe a heterogeneous 
network-based data set for alzheimer’s disease (HENa). additionally, we demonstrate the application 
of state-of-the-art graph convolutional networks, i.e. deep learning methods for the analysis of such 
large heterogeneous biological data sets. We expect HENa to allow scientists to explore and analyze 
their own results in the broader context of alzheimer’s disease research.
Background & Summary
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that progresses with age and eventually 
leads to death. Several approved drugs can be applied to reduce the symptoms of Alzheimer’s disease, however, 
no current treatments can modify the underlying disease processes1,2. A number of experiments have been per-
formed to understand the regulatory mechanisms of the disease3–6. The results obtained from such experiments 
are collected in various databases that were created for depositing and providing further access to similar types of 
experimental biological data such as ArrayExpress, IntAct, hu.MAP, and ADNI7–10.
The studies that utilize the results of such experiments address the causes of brain ageing by researching the 
mechanisms involved in this process. These studies are carried out to identify the molecular interactions through 
which the ageing phenotype develops in normal and disease conditions11–13. Analyses of various data types, like 
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protein-protein interactions (PPI), gene expression, and medical imaging, have uncovered substantial informa-
tion about disease mechanisms. The majority of such studies have focused on analysis of a particular experimental 
data type, resulting in the identification of several markers and biological interactions associated with Alzheimer’s 
disease2,11,14–16. However, since the disease-related data sets originate from many types of experiments, performed 
by scientists working in different domains such as proteomics, molecular biology, clinical diagnostics and genom-
ics, these data sets are not collected in a single repository and format, making it difficult to obtain a systems view 
of the molecular elements and interactions that are involved in the disease (Fig. 1).
As an approach to overcoming such limitations in the case of research related to Alzheimer’s disease, we pres-
ent here a HEterogeneous Network-based data set for Alzheimer’s disease. HENA results from an extensive data 
collection and is designed to allow prioritization of protein pairs using complementary information. It is accessi-
ble via the Network Data Exchange (NDEx) repository17–19 and via the figshare repository20. HENA was created to 
integrate Alzheimer’s disease-related data from well-known public data collections, as well as novel experimental 
and computational data sets generated by the members of the AgedBrainSYSBIO consortium21 (Fig. 2). We have 
generated computational data sets, i.e. data sets of epistatic and co-expression interactions, by utilizing data from 
Alzheimer’s disease-specific experimental data collections.
HENA combines 64 distinct computational and experimental data sets of six data types originating from nine 
data sources, as described in Online-only Table 1 and Fig. 2. These data types include protein-protein interac-
tions, gene co-expression, epistasis, genome-wide association studies (GWAS), gene expression in different brain 
regions, and positive selection data. We combine selected Alzheimer’s disease data, taking into account its incom-
pleteness, in an attempt to harmonize the existing large data collections.
One way of combining heterogeneous data sets of various types and formats is the transformation of these 
data sets into an intermediate form, such as a network22–24. This approach can be used to integrate many types 
of data as long as they contain a common unifying feature. We applied transformation-based integration by rep-
resenting individual interaction data set in the form of an edge list and combine them into one network, where 
edges represent biological relations and nodes represent biological entities such as genes, SNPs and proteins. 
Additionally, we collected data sets containing Alzheimer’s disease-related information about SNPs, genes and 
proteins. These data sets were then combined to constitute a table of node attributes. Thus, HENA consists of a 
network of heterogeneous biological interactions and a table of node attributes.
Recent advances in biological network analysis methods, i.e. the application of graph convolutional networks 
(GCN), have demonstrated that network structure carries rich information helping to effectively uncover under-
lying disease mechanisms and pathways23,25. In the description of a use case, we demonstrate how combined 
heterogeneous data sets in the network format can help to develop a better understanding of Alzheimer’s disease.
Methods
transformation-based integration overview. Bringing together individual data types undoubtedly 
enriches the systematic view on the Alzheimer’s disease, giving researchers the opportunity to understand molec-
ular mechanisms from the genetic to protein levels. However, it also involves some limitations of biological data 
integration due to its heterogeneous nature26 such as different formats and standards, lack of common name 
Fig. 1 Bringing together heterogeneous data related to Alzheimer’s disease. Diagram represents the enrichment 
of the knowledge about Alzheimer’s disease by combing genomics, proteomics and clinical phenotype data.
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space, incompleteness, versions of data collections, and size differences. Currently in the field of omics integra-
tion there is an open question about which molecular level should be used to provide a flexible and effective way 
to describe a biological system on different levels22,26. The answer to this question is highly dependent on the 
Fig. 2 Project pipeline. HENA brings together 64 preprocessed computational and experimental data sets. 
Epistasis, co-expression and aggregated gene expression data sets were computed by SIB and Quretec using 
original data sets from ADNI, TGEN, HBTRC, MEM and ABA data sources. PPI from IntAct data source were 
preprocessed and added to the collection. Data sets generated and provided by the consortium members, i.e. 
PPI related to brain ageing, positive selection and Alzheimer’s GWAS were added directly during the integration 
step. Data sets are colored based on the data type. i.e. epistasis is colored light green, co-expression is red, 
aggregated gene expression is dark red, PPI is violet, GWAS is yellow and positive selection is dark green. The 
individual data sets are acknowledged by citing the DOI. The final integrated data set has separate DOI and data 
authors.
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available omics data sets. Our approach is meant to allow the researchers to transit from one layer of information 
to the other by combining the individual layers of knowledge into one model. In our work we proposed an inte-
gration at the gene level, allowing researchers to go from SNPs to proteins to grasp more complete picture of the 
molecular interactions in Alzheimer’s disease.
We combine the heterogeneous experimental data from various sources into one heterogeneous 
network-based data set for Alzheimer’s disease. The HENA data set18,19 consists of two parts–a graph, describ-
ing biological interactions between genes, proteins, single nucleotide polymorphisms (SNPs), gene probes, and 
a set of node attributes providing additional information about the genes (Fig. 3). Gene interactions include 
protein-protein interactions, co-expression, and epistasis. Due to this variety of the interactions’ nature, the ori-
gin from various databases and experimental sources, there is a lack of unified node identifiers. To overcome 
this problem the identifiers of the proteins, SNPs, probes and gene names originating from various databases are 
mapped to one unique Ensembl name space27.
We represented each individual interaction data set in a form of the network (Fig. 3), where nodes stand 
for entities like proteins, genes, SNPs, etc., and where edges depict biological relations between the nodes, e.g. 
protein-protein interactions, co-expression, epistatic interactions. Multiple individual networks were then com-
bined into one network using the unifying feature. As a unifying feature we used genes onto which SNPs, tran-
scripts and proteins can all be mapped. We mapped identifiers from each individual data set such as SNP, protein 
and gene identifiers to a common name space. Due to the fact that genes or proteins coming from different 
databases might have a few alternative names, unique gene identifiers provided by Ensembl ver. 93 (ENSG ID) 
were used as a common name space. Each interaction A-B in the networks is described by the score, interaction 
type and the data set where the interaction can be found. A summary of edge attributes is presented in Table 1. 
Additional disease-related information about each node, e.g. GWAS association, positive selection, expression in 
the brain regions, is collected in the form of a table with the attributes described in Table 2. For each node a list 
of attributes is a vector of the length 237. In the sections below we describe how experimental and computational 
data sets were acquired, transformed and combined.
Fig. 3 Data integration pipeline. Preprocessed data sets contain information about the interactions between 
genes, proteins, SNPs, and information characterizing them, e.g. node attributes. Interaction data sets contain 
PPI, co-expression and epistatic interactions including IGRI as its sub-type. Node attributes originate from 
GWAS, positive selection and gene expression in brain regions from ABA. Integration was performed using 
transformation-based approach. Data sets from the interaction group were converted into intermediate graphs, 
where nodes are genes, proteins, SNPs and the edges are the relations such as PPIs (violet), epistatic interactions 
(green) or co-expression interactions (red). All individual node identifiers were mapped at the gene level and 
converted into the ENSEMBL name space. Individual graphs were then combined into one heterogeneous graph 
with possible multiple edges between two nodes. Additionally, each node has been characterized by a set of 
attributes such as ENSG ID, corresponding gene name, gene biotype, SNP ID, GWAS p-value, positive selection 
p-value and aggregated expression in 231 brain regions.
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Co-expression analysis. Co-expression in Alzheimer’s disease and healthy individuals was computed based 
on the selected six Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray gene expression data sets28–33 
from the Multi Experiment Matrix (MEM) database34. Data sets were obtained in NetCDF format and stored as a 
“Gene expression microarray datasets in NETCDF format from MEM database” part of HENA data collection at 
figshare repository20. These data sets were chosen manually based on the sample annotations. Selected data sets 
contain samples from patients with neurodegenerative disorders including Alzheimer’s disease (AD) and healthy 
individuals (HI) (E-MEXP-228028 (5 AD, 5 HI), E-GEOD-528129 (88 AD, 73 HI), E-GEOD-475730 (10 AD, 10 
HI), E-GEOD-2965231 (18 AD), E-GEOD-2814632 (22 AD, 8 HI), E-GEOD-1830933 (3 AD, 3 HI)). For further 
analysis we have selected only the samples related to the patients with Alzheimer’s disease (AD) and healthy 
individuals (HI).
We calculated the Spearman correlation between all pairs of probes in each data set and sort-ranked them 
based on the correlation value. In each data set the pair with the strongest correlation value received the highest 
rank (rank 1). Ranks obtained for each pair of probe sets in each data set were then normalized and aggregated 
using the Robust Rank Aggregation (RRA) method implemented in Robust Rank Aggreg R package35. The final 
RRA scores were adjusted for multiple testing using FDR method. We kept only the pairs where the RRA score 
is smaller than 1e−5. Similar to the p-value, the RRA score varies from 0 to 1. The smaller the score, the stronger 
the association between the pair of genes is. We carried out the computation of RRA scores at the probe set level, 
and later mapped Affymetrix probeset names to Ensembl ver.93 gene name space (ENSG ID) using gProfileR R 
package ver. 0.6.236. Multiple probe set names can correspond to the same unique ENSG ID. This one-to-many 
mapping problem has resulted in the presence of multiple correlated pairs consisting of genes with the same 
ENSG IDs but with different corresponding scores. Bearing in mind this issue, we have aggregated those pairs for 
the data set by selecting the maximum, i.e. the most conservative, value out of all scores in all duplicated pairs. 
Additionally, due to the non-symmetrical nature of the RRA scores for the pair of nodes A-B and B-A (where A 
and B are the correlated genes), we kept the most conservative value out of two scores. The resulting co-expression 
interactions were added to the HENA data set in a form of interaction between two nodes (ENSG.A–ENSG.B) 
and a score representing the RRA score (see Online-only Table 1 for details). The computations were executed in 
parallel at the HPC center of the University of Tartu using doParallel R package ver.1.0.1437.
Co-expression in disease-related brain regions. Gene co-expression analysis is a widely used method 
for the identification of possible functionally related genes and potentially interacting proteins38–40.
In this study co-expression analysis was performed using six Agilent 8 × 60 K whole-brain gene expres-
sion microarrays41–46 downloaded from Allen Human Brain Atlas (ABA)47. Combined data sets were 
quantile-normalized and filtered to eliminate probes with low variance. Data quality control for batch effect was 
performed using principal component analysis48. It has been previously demonstrated that the hippocampal cir-
cuit consisting of cornu ammonis sectors (CA1-CA4), dentate gyrus (DG), subiculum, and septal nuclei (SptN) 
are affected by Alzheimer’s disease1,49–54.
Edge attribute Description
ENSG.A ENSG IDs of the node A
ENSG.B ENSG IDs of the node B
Score
Value, associated with the interaction.
It represents the importance of an interaction,
i.e. strength, significance.
Interaction type Type of biological relation between node A and B,i.e co-expression, PPI, epistasis.
Data source ID in HENA
Short name of the data source of the interaction.
In case multiple data sets originate from one data source,
data source name is appended by individual data set.
Table 1. List of edge attributes.
Node attribute Description
ENSG ENSG ID of the node
Gene name Alternative human readable gene name.
Biotype Gene biotype according to Ensembl classificationi.e. protein coding, long non-coding, etc.
SNP ID SNP identifier from GWAS data set.
GWAS p-value P-value corresponding to SNPs from GWAS data set.
PS p-value P-value of gene association with positive Darwinian selection.
Brain region ID #1 Aggregated gene expression of the node in brain region ID #1
… …
Brain region ID #231 Aggregated gene expression of the node in brain region ID #231
Table 2. List of node attributes.
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We have extracted samples corresponding to these disease-associated regions from the combined data set 
using the tissue ontology provided along with the microarrays as a ref.55. The Spearman rank correlation coeffi-
cients and the corresponding p-values were computed for each probe pair in the data set using R package psych 
ver. 1.8.456. All p-values were adjusted using FDR correction. To select the probes with the reliable co-expression, 
we have filtered the results. On the first filtering step only the co-expressed pairs with the p-value ≤ 0.01 were 
kept. Additionally, these resulting pairs were filtered based on the correlation coefficient, selecting values ≥1st 
quartile of the positive correlation distribution and ≤3rd quartile of the negative correlation distribution to be 
included in HENA. The computations were executed in parallel at the HPC center of the University of Tartu using 
doParallel R package ver. 1.0.1437.
The resulting interactions were added to the HENA data set in the form of an interaction between two nodes, 
ENSG.A and ENSG.B, and a score representing the Spearman correlation coefficient. Co-expressions in each 
disease-related region is reported separately (see Online-only Table 1 for details).
Epistasis analysis. Epistatic effects were computed in three cohorts. The disease-associated traits that were 
used included the change in ventricular volume, derived from successive brain MRIs, scores from a panel of cog-
nitive traits tests and Braak staging reflecting the disease severity57. The epistatic interactions were computed as 
the departure from addtitivity of the effects of pairs of SNPs on phenotype, as detailed below.
Epistatic interactions between pairs of SNPs associated with change in ventricular volume20 detected in ADNI 
consortium10 patients were computed based on genotyping and longitudinal brain imaging data that were down-
loaded from the ADNI database58 provided by the ADNI consortium. We have used data from the subset of 719 
participants from the first phase of the ADNI project for whom both genome-wide genotype and MRI data were 
available.
The epistatic effects on quantitative traits of 400 Late-Onset Alzheimer’s Disease (LOAD) patients from ADNI 
cohort20 were detected analysing the relation between GWAS genotypes and the set of 23 cognitive traits regu-
larly assessed in these patients. The list of all 23 cognitive traits is available in Table 3. Measurements of cognitive 
traits were available at time points which varied from one individual and trait to the other, in number, frequency, 
and relation with age or time of diagnosis. Bearing this in mind, two values were used for the assessment of each 
cognitive trait – CT_latest the last value assessed for each patient, and CT_slope the slope of the line fitted by 
linear regression to successive values assessed for each patient. Slope value serves as a quantification of the trend 
of a given trait, i.e. the rate at which it changes over time. Due to the fact that AD is a progressive disease, and 
the ADNI cohort is composed of individuals of various age and disease stage, such data derivation may be more 
significant than absolute instantaneous value, especially in individuals in the early stages of disease development. 
Altogether computation of the epistatis effects resulted in 23 × 2 data sets (see Online-only Table 1).
Epistatic interactions between pairs of SNPs associated with Braak staging in TGEN cohort20 were detected 
through a genome-wide analysis of epistatic effects in the AD case-control cohort available from the Translational 
Genomics Research Institute59. The TGen II cohort included 1599 Caucasian individuals (1,014 AD cases, 585 
controls), collected by TGen, as has been described60. Data from 915 patients with available genotypes and Braak 
scores were used (613 AD cases, 302 controls).
Epistatic interactions between SNPs associated with Braak staging20 were computed in Harvard Brain Tissue 
Resource Center cohort61. The 803 individuals in HBTRC cohort comprise 388 AD cases, 220 Huntington’s dis-
ease cases and 195 controls matched for age, gender, and post-mortem interval (PMI). The tissue specimens were 
provided by the HBTRC.
Epistasis was detected using a linear modelling approach, as implemented in the FastEpistasis software62. Briefly, 
to test for the presence of an epistatic effect of two SNPs on a phenotype, the relation between the value of the trait 
and the allele dosages at these two loci was modelled as the combination of separate additive effects and of a multi-
plicative effect. The model was fitted by linear regression, and the presence of epistasis assessed based on the F test 
p-value of the coefficient for the multiplicative term, relative to the hypothesis of a null effect. The significance of each 
interacting SNP pair is characterized by p-value < 1e−8 for the association with changes related to ventricular volume 
and Braak score and p-value < 1e−5 for the association with cognitive traits. The computation was run in parallel at 
the HPC center of the Vital-IT group at SIB, using software versions optimized to the diverse processor (intel(R) 
Xeon(R)) architectures and parallelization paradigms (OpenMP, MPI, Hybrid) available in this compute cluster.
Mapping of SNPs to genic and intergenic bins SNP IDs, for which genotype data were available, were mapped 
on genomic regions using the Ensembl database accessed via R package biomaRt ver. 2.28.063. To make complete 
use of these genome-wide genotypes, we considered not only regions where genes are located, but also inter-
genic regions (IGR). The SNPs located within the boundaries of a gene, including a margin of 5k base-pairs on 
each side, were assigned to this gene and mapped to the corresponding ENSG ID. The SNPs located outside of 
these boundaries were assigned to the intergenic region delimited by two flanking genes. Each of these IGRs was 
uniquely identified by the combination of the ENSG IDs of the flanking genes. In this study we refer epistatic 
interactions that contain an IGR as inter genic region interactions (IGRI). Consult Online-only Table 1 to see the 
data sets containing IGRI. As genes may overlap, a single SNP may be assigned to multiple genes. Conversely, it 
can only be assigned to a single intergenic region. In the following, we refer to both gene regions and intergenic 
regions as “bins”. A region-wise Bonferroni correction method was used to adjust for multiple testing. The critical 
significance level alpha was adjusted separately for each pair of bins considered, using as the correction coefficient 
the number of pairs formed by the combination of SNPs located in the two bins.
Epistatic interactions were added to the HENA data set in the form of interaction between two nodes, node 
1–node 2, with the corresponding ENSG.A and ENSG.B and a score, representing a p-value of an interaction. 
In the case of IGRI, the interacting nodes can be represented, for example, as ENSG.C–ENSG.D for node1 and 
ENSG.E–ENSG.F for node2, respectively, whereas ENSG.C, ENSG.D, ENSG.E, and ENSG.F are the flanking 
genes of the intergenic region.
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Yeast two-hybrid data generation and analysis. The yeast two-hybrid PPI data set of proteins related 
to brain ageing was produced by the Aged Brain SYSBIO consortium64. Studying the interactions between the 
proteins can reveal their function, and provide information about biological processes they participate in, includ-
ing neurodegenerative diseases like Alzheimer’s disease.
All the baits were cloned using standard procedure after PCR amplification and the validity of the sequence 
was checked by full sequencing. The baits were used to screen a random-primed cDNA library constructed into 
the pP6. Human Brain (HBR) cDNA library. The prey fragments of the positive clones were amplified by PCR and 
sequenced at their 5′ and 3′ junctions. The resulting sequences were used to identify the corresponding interact-
ing proteins in the GenBank database (NCBI) using a fully automated procedure. A confidence score (PBS, for 
Predicted Biological Score) was attributed to each interaction as previously described65. The protein interactions 
from this publication have been submitted to the IMEx consortium66 through IntAct8 and assigned the identifier 
IM-26801. Protein identifiers from the resulting PPI data set were mapped onto ENSG IDs using R package gPro-
fileR36. The corresponding interactions were added to HENA data set in a form of interaction between two nodes 
ENSG.A–ENSG.B and a score representing PBS (please see Online-only Table 1 for details).
Filtering of the protein-protein interactions from Intact data sets. Three data sets of human 
protein-protein interactions were downloaded from the IntAct database version 4.2.68 – a human interaction data 
set67, a data set of expert-curated PPIs based on proteins with an association to Alzheimer disease (http://www.
ebi.ac.uk/intact/query/annot:%22dataset:alzheimers%22), and a data set of PPI based on proteins with an estab-
lished role in the presynapse (http://www.ebi.ac.uk/intact/query/annot:%22dataset:synapse%22). To keep inter-
actions with medium or high confidence, as suggested by IntAct domain experts, we kept the data with the IntAct 
MI score ≥ 0.45. Data sets for human interactions were selected based on the following search criteria “(taxid: 
9606 (human)) AND intact-miscore: [0.45 TO 1]”. Since the data sets also contained some interactions between 
human proteins with proteins of other species, we additionally filtered curated data sets ADIA and SIA based 
on the human taxonomy ID 9606 to select human-specific interactions. Protein names from the original data 
sets were mapped to Ensembl ver.93 gene name space (ENSG ID) using R package gProfileR36. The interactions 
between protein.A and protein.B were added to the HENA data set in a form of interaction ENSG.A–ENSG.B 
with the corresponding MI score68 (see Online-only Table 1 for details).
Combining individual interaction data sets. Individual data sets of co-expression, epistasis and 
protein-protein interactions in the form of edge lists, obtained as described in the previous Methods sections, 
were combined into one data set. This data set can be represented as a heterogeneous graph, with nodes represent-
ing genes, and edges representing biological relations between the genes. HENA data set network structure18,19 is 
illustrated as a graph in Fig. 3 and represented as an example edge list in Table 4.
Additionally, each node in the HENA data set is characterized by a set of attributes (“HENA NODE 
ATTRIBUTES” part of HENA data collection deposited at figshare repository)20, such as gene name, biotype69, 
GWAS p-value, positive selection p-value and gene expression in the 231 brain region. The acquisition of the 
individual attributes and the process of combining these attributes are described in the sections below.
Trait name Abbreviation
Alzheimer’s Disease Assessment 11-items composite score ADAS11
Alzheimer’s Disease Assessment 13-items composite score ADAD13
Clinical Dementia Rating Scale CDRSB
Everyday Cognition. Participant self report. Divided Attention Ecog_PtDivatt
Everyday Cognition. Participant self report. Language Ecog_PtLang
Everyday Cognition. Participant self report. Memory Ecog_PtMem
Everyday Cognition. Participant self report. Organization Ecog_PtOrgan
Everyday Cognition. Participant self report. Planning Ecog_PtPlan
Everyday Cognition. Participant self report. Visuospatial Ecog_PtVisspat
Everyday Cognition. Participant self report. Total Ecog_PtTotal
Everyday Cognition. Study partner clinician report. Divided Attention Ecog_SPDivatt
Everyday Cognition. Study partner clinician report. Language Ecog_SPLang
Everyday Cognition. Study partner clinician report. Memory Ecog_SPMem
Everyday Cognition. Study partner clinician report. Organization Ecog_SPOrgan
Everyday Cognition. Study partner clinician report. Planning Ecog_SPPlan
Everyday Cognition. Study partner clinician report. Visuospatial Ecog_SPVisspat
Everyday Cognition. Study partner clinician report. Total Ecog_SPTotal
Functional Activities Questionnaire FAQ
Montreal Cognitive Assessment MOCA
Mini-Mental State Examination MMSE
Rey Auditory Verbal Learning Test. Immediate RAVLT_Immediate
Table 3. List of cognitive traits in ADNI cohort.
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Gene expression in the brain regions. The same preprocessed six whole-brain microarray data sets from 
the Allen Human Brain Atlas41–46 were used to compute the aggregated gene expression in the 231 brain region 
annotated in the meta data accompanying the microarrays. Expression values for each gene in samples related 
to the individual brain region in all six brains were aggregated in a form of Z-scores. We first calculated mean 
expression values for each probe across all samples per region in each of the six data sets. We then calculated 
Z-scores over mean gene expression values in each individual region. The probe IDs were mapped to Ensembl 
ver.93 gene name space (ENSG ID) using gProfileR R package ver. 0.6.236. In cases where two or more probe sets 
were mapped onto the same ENSG ID, the probe with absolute the maximum Z-score was kept in the data set.
LoaD GWaS analysis. International Genomics of Alzheimer’s Project (IGAP)14 is a large two-stage study 
based upon genome-wide association studies (GWAS) on individuals of European ancestry. In stage 1, IGAP 
used genotyped and imputed data on 7055881 single nucleotide polymorphisms (SNPs) to meta-analyse four 
previously-published GWAS data sets consisting of 17008 Alzheimer’s disease cases and 37154 controls (the 
European Alzheimer’s disease Initiative, the Alzheimer Disease Genetics Consortium, the Cohorts for Heart and 
Aging Research in Genomic Epidemiology consortium, the Genetic and Environmental Risk in AD consortium). 
In stage 2, 11632 SNPs were genotyped and tested for association in an independent set of 8572 Alzheimer’s dis-
ease cases and 11312 controls. Finally, a meta-analysis was performed combining results from stages 1 & 270. The 
resulting GWAS p-values from meta analysis of stages 1 and 2 were used as one of the node attributes. We have 
filtered the data set and kept SNPs with p-value ≤ 0.05. Original SNP IDs were converted to Ensembl name space 
ver. 93 using biomaRt R package ver. 2.28.063 and combined with the set of node attributes (for details see section 
Aggregation of the node attributes). Mapping of the multiple SNP IDs to the same ENSG ID resulted in multiple 
corresponding records in the resulting data set. At the step of combining node attributes, we kept the original SNP 
ID as one of the node attributes (see section Combining node attributes for details).
Positive selection analysis. In order to characterize the evolutionary dynamics in genes that are associated 
with Alzheimer’s disease, we analyzed the SNP data from IGAP14,70. We first mapped the 500 most significant 
SNPs onto their encoded human genes. As many SNPs mapped to the same genes, we removed duplicates, yield-
ing a list of 42 unique genes.
These genes were converted to ENSG IDs and 1 to 1 orthologs for each of the corresponding human genes 
were searched across 41 mammalian species described in the tree of mammalian species topology. When query-
ing the Ensembl database, only genes with transcripts whose status is “known” and “coding” were retained. Only 
36 of the genes matched these criteria. In cases for which more than one transcript was available per human gene, 
the longest one was retained. In cases where more than one transcript was available for each of the mammalian 
orthologs, the transcript with the highest71 score against the retained human transcript was chosen. This pro-
cedure resulted in 23 genes for which at least 4 orthologs were collected. Codon multiple sequence alignments 
(MSA) for each of these sets were computed by first aligning the translated protein sequences using MAFFT 
v7.18272 and then back-translating this MSA to nucleotide-based alignment.
We next searched for positive Darwinian selection in each orthologous group. Two types of tests were con-
ducted, site test and site-branch test. Both tests were conducted using PAML version 473. For each gene, a mam-
malian species topology based on current literature74–77 was pruned to include only the species for which Ensembl 
orthologs were found. Each such pruned topology, together with the codon MSA, were provided as input into the 
PAML program. Out of the 23 genes 14 were shown to evolve under a positive selection regime using the site test 
based on FDR-corrected p-value ≤ 0.05. This data set is available as “Positive Darwinian selection” part of HENA 
data collection deposited at figshare repository20.
We next tested whether each gene experienced positive selection only in the branch leading to Homo sapiens. 
To test this hypothesis, we used the site-branch test72. In this test, the alternative model allows some sites to expe-
rience positive selection only in the lineage leading to Homo sapiens. However, no support for human-specific 
positive selection using this test was found.
The positive selection p-values were added to the list of node attributes. The values of this attribute is available 
for the genes shown to evolve under a positive selection regime using the site test.
Combining node attributes. Ensemble ver. 93 gene names corresponding to the nodes in the HENA 
data set, e.g. proteins, genes and SNPs, were extracted from all individual processed data sets (Fig. 3) as it was 
described in the previous sections. To ease the usage of the integrated data set, Ensembl gene identifiers were con-
verted also to gene names. Corresponding gene biotype according to Ensembl classification69 was extracted for 
each node using biomaRt R package ver. 2.28.0. Nodes with pseudogene biotypes were filtered out. Additionally, 
ENSG.A ENSG.B Score Interaction type
Data set ID in 
HENA
ENSG00000129484 ENSG00000167972 0.0001 PPI PBA
ENSG00000119917 ENSG00000119917 0.68 PPI ADIA
ENSG00000022355 ENSG00000000005 0.7238095 co-expression ABA_CA1
ENSG00000050767 ENSG00000070950 9.30682e-09 epistasis TGEN
… … … … …
Table 4. Example of the interactions representation as an edge list.
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the interactions containing these nodes were also removed from the HENA data set. Individual gene attributes, 
i.e. ENSG ID, gene name, biotype, SNP ID, GWAS p-value, positive selection p-value and expression in the 231 
brain region, were merged based on ENSG ID resulting in a vector of 237 attributes for each node20 (see Table 2).
Data Records
This section describes data records originating from the preprocessed 64 individual data sets that comprise the 
HENA data set. For a compact description of the 46 data sets associated with cognitive traits, they are described 
in one data record 5. HENA data set consists of two parts, a graph, describing biological interactions (see Data 
records 1–10) between genes, proteins, SNPs, probes and a set of node attributes providing additional infor-
mation about the genes (see Data record 11). A summary of the HENA data set is demonstrated in Fig. 4 and 
Online-only Table 1.
Data record 1 - gene co-expression in AD and normal brain. Gene co-expression describes the corre-
lation between changes in gene expression levels across multiple samples and biological conditions. The main idea 
is that two genes that have correlated expression across multiple biological conditions are more likely to encode 
interacting proteins78, i.e. proteins involved in the pathological disease processes. This data record represents a 
data set of gene pairs co-expressed in Alzheimer’s disease patients and healthy individuals. It can be downloaded 
as an individual data set “ADN precomputed gene co-expression in Alzheimer’s disease and healthy samples” 
from HENA data collection deposited at figshare repository20 or as a part of the integrated HENA data set18,19. 
Each co-expressed gene pair is described by a Robust Rank Aggregation (RRA) score35, ranging from 0 to 1 (the 
lower the score, the smaller the rank of the corresponding interaction). A summary of the attributes’ values asso-
ciated with gene co-expression is shown in Online-only Table 1.
Data record 2. Co-expression in disease-related brain regions. The development of AD pathology is 
not homogeneous across the brain. It has been shown that there are a number of brain regions such as hippocam-
pal cornu ammonis sectors (CA1–CA4), dentate gyrus (DG), subiculum, and septal nuclei (SptN) which are 
affected by Alzheimer’s disease1,49–54. The pathological formation of amyloid-β plaques as well as the aggregation 
of the microtubule protein Tau forming neurofibrillary tangles lead to neuronal loss. Co-expressed gene pairs in 
these brain regions can help to identify the interacting proteins involved in the disease pathways. Co-expression 
in the disease-associated regions was computed using whole-brain microarray data sets downloaded from the 
Allen Brain Atlas47. The analysis resulted in seven individual co-expression data sets described in Online-only 
Table 1 and Fig. 2. These data sets can be downloaded as individual data sets “Co-expression in CA1 brain region”, 
“Co-expression in CA2 brain region”, “Co-expression in CA3 brain region”, “Co-expression in CA4 brain region, 
“Co-expression in DG brain region”, “Co-expression in subiculum brain region”, “Co-expression in SptN brain 
region” from HENA data collection available at figshare repository20 or as a part of the integrated HENA data set 
at NDEx repository18,19. Each co-expressed gene pair is characterized by a Spearman rank correlation coefficient. 
The association can be described as a positive or negative correlation. While a positive correlation can potentially 
indicate protein interaction and activation mechanism, a negative correlation will represent a scenario of the 
decrease in gene expression of one of the genes with the increase in the expression of its co-expressed partner 
leading to the suppression mechanism. The higher the absolute coefficient value, the stronger the co-expression 
between the genes is.
Data record 3 - epistatic effects of pairs of SNPs on change in ventricle volume in ADNI 
cohort. Epistasis is an effect of interaction between two or more SNPs of different genes on a phenotype devi-
ating from their individual effects79,80. These effects are especially interesting in the cases of complex traits such an 
Alzheimer’s disease. Change in ventricular volume detected on a patient’s MRI can serve as an indicator of brain 
tissue loss during the progression of dementia81,82. The data record represents epistatic effects of pairs of SNPs on 
change in ventricle volume detected in ADNI consortium10 patients (ADNI_VER). A summary of epistatic inter-
actions in ADNI_VER is shown in Online-only Table 1. This data set is available for download as an individual 
data set “Epistasis Alzheimer’s Disease Neuroimaging Initiative (ADNI_VER)” from HENA data collection at 
figshare repository20 and as a part of the integrated data collection18,19.
Data record 4 - epistatic interactions associated with Braak score in TGEN cohort. This data 
record is a data set of epistatic interactions between pairs of SNPs associated with Braak staging57 detected in the 
TGEN cohort (TGEN). Braak staging reflects the disease severity of Alzheimer’s disease based on pathophysio-
logical changes in the brain.
A summary of the epistatic interactions in TGEN is shown in Online-only Table 1. The data set “Epistasis 
Translational Genomics Research Institute (TGEN)” is available for download individually from HENA data 
collection at figshare repository20 and as a part of the HENA integrated data set18,19.
Data record 5 - epistatic interactions associated with Braak score in HBTRC cohort. This data 
record represents epistatic interactions between pairs of SNPs associated with Braak staging57 detected in the 
Harvard Brain Tissue Resource Center cohort (HBTRC). The summary of the HBTRC data set is depicted in 
Online-only Table 1. The data set “Epistasis Harvard Brain Tissue Resource Center (HBTRC)” is available for 
download individually from HENA data collection at figshare repository20 and as a part of the integrated HENA 
data set18,19.
Data record 6 - epistasis interaction associated with cognitive traits in ADNI cohort. The dis-
ease’s progression can be described by a number of features such as changes in memory, attention and language. 
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These features combined can characterize specific quantitative traits associated with the progression of dementia. 
This data record is comprised of 46 data sets of epistatic effects on 23 quantitative traits (see Table 3) of LOAD 
patients from the ADNI cohort. The summary of data sets and the corresponding data identifiers used in HENA 
are shown in Online-only Table 1. These 46 data sets are available for download in the form of a combined data 
set of epistatic effects on cognitive traits “Epistasis cognitive traits (ADNI_CT)” from HENA data collection at 
figshare repository20 and as a part of the integrated HENA data set18,19.
Data record 7 - PPI involved in brain ageing. This data record describes newly characterized PPIs 
involved in brain ageing (PBA) including interactions between gene products from the late-onset Alzheimer’s dis-
ease genome-wide association study (LOAD-GWAS). The interactions were obtained using the yeast two–hybrid 
method. Each interaction is described by the predicted biological score (PBS). The PBS scores have been shown 
to positively correlate with the biological significance of the interactions83,84. A summary of the protein-protein 
interactions is shown in Online-only Table 1. Data are available for download as an individual data set64 and a 
preprocessed version as a part of the integrated data collection18–20.
Data record 8 - PPI from IntAct in human. The data set contains information about medium and highly 
confident protein-protein interactions in humans that are available from the IntAct molecular interaction data-
base8. The confidence level of each interaction is characterized by an IntAct MI score68; larger scores correspond 
to a higher confidence level. A summary of this data record is shown in Online-only Table 1. This data set can be 
downloaded as an individual fail “intact_int.txt” located under section “Preprocessed PPI data sets from IntAct 
included in HENA” of HENA data collection deposited at figshare repository20 and as a part of the integrated data 
collection18,19.
Fig. 4 Counts of the interactions in the individual data sets comprising HENA data set. Each bar corresponds 
to the individual data set. Colors indicate interaction types: co-expression, PPI, epistasis ans IGRI. The number 
on top of the bar states the number of interactions.
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Data record 9 - alzheimer’s disease PPI from IntAct. Alzheimer’s disease PPI from IntAct (ADIA) 
is a subset of the expert-curated PPI data set based on the proteins with an association to Alzheimer’s disease85 
available from the IntAct molecular interaction database (http://www.ebi.ac.uk/intact/query/annot:%22data-
set:alzheimers%22, 2017)8. The confidence level of each interaction is characterized by an IntAct MI score as 
described in Data record 8. Data were filtered as described in the Methods section. A summary of this data record 
is shown in Online-only Table 1. The filtered data set is available for download as a part of the integrated data 
collection18,19 and as an individual fail “alz_intact_int.txt” under “Preprocessed PPI data sets from IntAct included 
in HENA” section of HENA data collection deposited at Figshare repository20.
Data record 10 - synaptic PPI from IntAct. The synaptic PPI data set from IntAct (SIA) contains auto-
matically selected protein-protein interactions from the IntAct database8 with an established role in the presyn-
apse (http://www.ebi.ac.uk/intact/query/annot:%22dataset:synapse%22, 2017). A selected set of interactions is 
comprised of protein pairs where at least one protein has an established link to the synapse. The confidence level 
of each interaction is characterized by an IntAct MI score as described in Data record 8. The data set was filtered 
as described in the Methods section. A summary of this data set attributes is depicted in Online-only Table 1. The 
filtered data set is available for download as a part of the integrated data collection18,19 and as an individual fail 
“syn_intact_int.txt” under “Preprocessed PPI data sets from IntAct included in HENA” section of HENA data 
collection deposited at figshare repository20.
Data record 11 - aggregated information about the gene. The data record contains combined infor-
mation about all nodes involved in the interactions described in the HENA data set18,19. Each node in this data 
set represents a gene, protein, SNP or probe that is uniquely identified by its Ensembl gene name, and is charac-
terized by a set of attributes (Fig. 3 and Table 2). This data record combines preprocessed GWAS data set related 
to Alzheimer’s disease (“Preprocessed GWAS data included in HENA)20, a data set of genes showing positive 
selection (“Positive Darwinian selection”)20, and a data set of gene expression in brain regions (“Aggregated gene 
expression in six whole-brain microarray datasets”)20. Individual gene attributes, i.e. ENSG ID, gene name, bio-
type69, SNP ID, GWAS p-value, positive selection p-value and expression in the 231 brain region are combined 
based on ENSG ID and represent a vector of 237 attributes for each node (see Table 2). A summary of this data is 
presented in Online-only Table 1.
The data record also contains information about the association of 11,632 SNPs mapped onto ENSGs with 
Alzheimer’s disease70 based on a genome-wide association study performed by the International Genomics of 
Alzheimer’s Project14. Aggregated data about each gene also includes the information about positive Darwinian 
selection produced by the AgedBrainSYSBIO consortium (“Positive Darwinian selection” data set)20. Additionally, 
each gene in the data set is characterized by its biotype and gene name according to Ensembl database ver.93.
technical Validation
Microarray gene expression preprocessing. The raw .CEL files and annotations of Affymetrix 
GeneChip Human Genome U133 Plus 2.0 microarray data sets28–33 were downloaded from ArrayExpress7 and 
preprocessed according to MEM standard operation pipeline34. The samples were quantile-normalised and back-
ground corrected using the just.rma() function from affy R package86 with default parameters. Preprocessed 
data sets were converted into NetCDF format using ncdf4 R package87. Probe set expression profiles in each 
normalized data set were filtered based on the standard deviation (SD) >0.29 to eliminate the probe sets with low 
variance. Additionally, only samples related to Alzheimer’s disease and healthy controls were selected for further 
analysis.
For the co-expression analysis in disease associated regions, six Agilent 8 × 60 K whole-brain gene expres-
sion microarrays41–46 were downloaded from the Allen Human Brain Atlas47. Data sets were normalized and 
background-corrected by data authors as described in technical white paper “Microarray data normalization88”. 
Additionally, combined data sets were quantile-normalised and filtered based on standard deviation to eliminate 
probes with low variance. Principle component analysis was applied to identify possible batch effects. The ontol-
ogy of physiological brain structure that was used in the study is described in technical white paper “Ontology 
and nomenclature in the Allen Human Brain Atlas”89.
Selecting the co-expression interactions. To ensure the selection of the reliable co-expression interac-
tions, we have applied the following strategy. In the computations of the co-expression in disease-specific brain 
regions, in addition to the Spearman correlation coefficient, we have computed the significance level of each 
correlation using R package psych ver. 1.8.456. The obtained p-values were FDR-corrected. Only interactions 
with p-value ≤ 0.01 were retained. Weakly co-expressed pairs were removed based on the distribution of the 
correlation coefficient. We kept the interactions with correlation values ≥1st quartile of the positive correlation 
coefficient distribution and ≤3rd quartile of the negative correlation coefficient distribution.
In the computations of co-expression in Alzheimer’s disease and non-disease samples, the resulting scores 
were reported in the form of an RRA35 score. These scores have been FDR-corrected and filtered based on a 
threshold of ≤1e−5 to ensure the reliability of the reported results.
Genotyping and quality control. Genomic DNA samples were analyzed on different platforms in the 
three cohorts (ADNI, HBTRC, TGEN), as previously described in publications from respective institutions or 
consortiums.
TGEN cohort samples were genotyped on the Genome-Wide Human SNP 6.0 Array (Affymetrix, Inc., Santa 
Clara, CA, USA). Genotypes were called using Birdsuite. Standard quality control filters regarding minor allele 
frequency (MAF > 0.01), missing rate per marker and per individual (>0.15), and Hardy-Weinberg equilibrium 
1 2Scientific Data |           (2019) 6:151  | https://doi.org/10.1038/s41597-019-0152-0
www.nature.com/scientificdatawww.nature.com/scientificdata/
(p < 1e−6) were applied using PLINK. The resulting data, available for 1599 subjects and 759916 markers, were 
downloaded in PLINK format from TGen59.
HBTRC cohort samples were genotyped on the Illumina HumanHap650Y array (Illumina, Inc., San Diego, 
CA, USA) by the Merck Research Laboratories. Genotype data (Version 01, 2011-01), available for 741 sub-
jects and 555091 markers, were downloaded from the Sage Data Repository61. The Sage Data Repository dataset 
entry61 has been modified since the original dataset was downloaded at April 28th 2015 from https://synapse.
sagebase.org/#Synapse:syn4505. Thus we have stored the dataset used by us as part of the HENA data collection 
available via figshare repository20.
ADNI cohort samples were assayed using Human610-Quad BeadChip (Illumina, Inc., San Diego, CA, USA), 
which features a genome-wide selection of 620901 tag SNPs. GenomeStudio v2009.1 (Illumina) was used to gen-
erate SNP genotypes from bead intensity data90. The resulting data, available for 757 subjects, were downloaded 
in PLINK format from the ADNI repository58. As the two SNPs (rs429358, rs7412) that define the APOE epsilon 
alleles are not on the Human 610-Quad Bead Chip, APOE genotyping was performed separately, using restriction 
isotyping by gene amplification and cleavage with HhaI91. ADNI quality control steps included removing copy 
number variant probes as well as checking strand, base pair position, and allele specificity92,93.
Filtering of individuals and markers. Additionally, SNPs were excluded according to the following cri-
teria, call rate <0.1, minor allele frequency (MAF) <0.05, discrepancy relative to Hardy-Weinberg equilibrium 
(p ≤ 1e−3). Finally, tests for epistatic effects was limited to SNP pairs for which the product of the MAFs was 
greater than 0.01.
adjustment of Braak score phenotype. The Braak score is a semi-quantitative ordinal variable describ-
ing the extent of AD-characteristic alterations of neural tissue, from post-mortem examination of histological 
preparations. It defines six levels, from normal stage 1 to the most severe neuronal loss and accumulation of 
amyloid-beta plaques and neurofibrillary tangles corresponding to the stage 6. It is well known that Braak score 
increases with age, even in cognitively normal individuals. To adjust for this, the effect of age was estimated by 
loess regression, and subtracted from the observed score prior to analysis of epistatic effects.
adjustment of change in ventricular volume phenotype. Segmentation of cerebral ventricles and 
other brain structures on MRI images was performed at UCSF with the Freesurfer image analysis suite94, and the 
volumes reported in the ADNIMERGE data table58. In our study we have used the content of this table down-
loaded from the ADNI repository on January 30, 2014. The evolution of ventricular volume over time in each 
subject was characterized by the slope of a linear regression line fitted on the individual’s time-series of volume 
measurements, using the lm() function in R95, for a total of 621 subjects having at least two time-points, out of the 
757 subjects with genotype data. To account for confounding effects of major covariates, a multiple linear model 
of the effects of age, gender and baseline disease status was fitted to the ventricle volume increase rates, using the 
lm() function in R95. The residual ventricle variation that remained unexplained by these covariates was used as 
the input for analysis of genetic epistatic interactions.
Clone selection in yeast two-hybrid. Yeast two-hybrid screening was performed by Hybrigenics Services, 
S.A.S., Paris, France. The baits were fused to the C-terminal (LexA-bait, pB27) or the N-terminal (bait, lexA). The 
choice was made given the topology of the protein and knowledge available on functional fusion in mammalian 
cell. pB27, pB29 and pP6 were derived from the original pBTM11696 and pGADGH97 plasmids, respectively. 
For baits with very few positive clones in the less selective media, using the LexA-based plasmid, the same bait 
fragments have been sub-cloned in Gal4-based plasmids pB66 (Gal4-Bait) or pB43 (Bait-Gal4) and submitted to 
a new screen process pB66 and pB43 derive from pAS2DD98. For three baits (CELF1, FYN full length, MCF2L), 
the classic construct was too toxic to assure a saturated screening of the library and these were transferred into a 
centromeric met25 inducible vector and the induction of the bait was obtained in the selective media using minus 
methionine selective plates.
The screened Human Brain HBR cDNA library is a random primed library with a complexity of more 
than 50 million independent clones in E. coli and 10 million independent clones in yeast. The libraries were 
screened using a mating approach with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, mat α) containing the 
pre-transformed libraries and L40 ΔGal4 yeast strains containing the baits as previously described98. This method 
allows full coverage of the library. Potential auto-activation or stickiness of the bait was compensated by the use of 
3-aminotriazole (3-AT). The number of selected clones by million diploids was maintained below 10 with a mean 
of 1.2. The selectivity of the screen was then maintained to limit the background.
Selecting reliable PPI. The current data set includes a yeast two-hybrid data set generated by the consor-
tium and three data sets from IntAct database8. The confidence of the PPI can be evaluated based on the corre-
sponding score.
Yeast two-hybrid PPIs are characterized by a PBS score83,84. The PBS relies on two different levels of analysis. 
Firstly, a local score takes into account the redundancy and independence of prey fragments, as well as the dis-
tribution of reading frames and stop codons in the overlapping fragments. Secondly, a global score takes into 
account the interactions found in all the screens performed using the same library. This global score represents 
the probability of an interaction being nonspecific. The score ranges from 0 to 10 (the smaller the score, the more 
specific the interaction). In the HENA data set, we did not enforce any filtering on PBS, leaving the opportunity 
for the user to decide what threshold for the interactions is the most desirable.
Interactions from the IntAct database are characterized by the MI score. It is based on the manual annotation 
of every instance of a binary interaction within the IntAct database, taking into account information about the 
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interaction detection method, interaction type, and the number of publications the interaction has appeared in. 
The cumulative score is normalized between 0 and 1 across the entire IntAct database, with 1 representing an 
interaction with the highest confidence. The interactions added to HENA were selected based on the medium to 
high confidence level corresponding to MI score range [0.45; 1].
Detecting positively selected genes. Two types of tests were conducted to identify positively selected 
genes as described in the Methods section. The resulting p-values were adjusted for multiple comparisons using 
the FDR method. Genes evolving under a positive selection regime were chosen based on p-value ≤ 0.05.
Comparison with public databases. Although there is no alternative Alzheimer’s disease-specific data-
base or data set such as HENA available to our knowledge, we have selected for the comparison two widely used 
general-purpose databases that use network structure as underlying architecture of the data representation. We 
have compared the Alzheimer’s disease-specific PPI, co-expression and epistatic interactions collected in HENA 
with the interactions of the matching type from STRING99 and GeneMANIA100. Comparisons were conducted 
for the pairs of interacting nodes. While GeneMania reports interactions using ENSG IDs, STRING uses Ensembl 
protein identifiers. For the sake of consistent comparison we have mapped Ensembl protein identifiers to ENSG 
IDs. It is not a trivial task to find a suitable data source for the comparison of epistatic interactions due to the lack 
of such resource. We have compared the epistatic interactions with genetic interactions from GeneMania solely as 
the STRING database does not contain similar interaction types. We have excluded IGRIs from the comparison 
due to the lack of similar types of interactions in these two public databases. All data sets were prepared for the 
comparison by keeping only binary undirected interactions in the form of ENSG.A-ENSG.B. The overlapping 
interactions of the same type were counted and visualized using UpSetR R package101 for the visualization of 
intersecting sets. The results of the comparison are displayed in Fig. 5.
Comparison of the computational data sets such as co-expression and epistasis is highly dependent on the 
conditions used to produce a particular data set. Therefore, substantial discrepancies are possible when com-
paring computational data sets obtained in different setups, i.e. disease- and phenotype-specific co-expression 
and epistatic interactions might differ from the interactions reported for other conditions. Additionally, the dis-
crepancy between the number of overlapping interactions can be caused by the difference in how frequently data 
sources are being updated and criteria for the interactions to be included into a database. For example, in the case 
of the PPI comparison we found out examples of PPIs, such as MAD1L1 - LMO3 with a MI score of 0.49, that 
is considered to be interaction with medium-high confidence by IntAct, but they were not present in STRING 
database as was expected because STRING includes interactions from IntAct. There are a few reasons why inter-
actions may not appear in STRING. Firstly, STRING is updated every two years. Secondly, the data sets imported 
to STRING are re-benchmarked for each interaction A-B, taking into account the number of cliques and the 
number of interacting partners for both proteins A and B in the particular data set.
Usage Notes
The HENA data set18 is available from the NDEx repository17 which allows convenient sharing and exchange 
of network data sets. Due to the difficulty of incorporating the nodes representing IGRs, we have omitted them 
from the data set shared via the NDEx repository18,19. However, HENA with IGR nodes is available from the 
figshare repository20 in a tab-separated format. Besides full version of HENA18, we have created a reduced ver-
sion19 that sets a much more restrictive threshold (co-expression coefficient ≤−0.8 and ≥0.8) for the inclusion of 
co-expression edges described in Data record 2. This reduced version of HENA19 is aimed to be used by a biologist 
in simple operations such as exploring a network neighborhood around genes of interest. Both versions of HENA 
can be viewed and queried based on the filters available at the web user interface of NDEx repository, and further 
opened and manipulated in Cytoscape24 as described in the NDEx user manual102.
The expanding volume and variety of data across different biological domains allows researchers to analyze 
these diverse data and integrate them with their own work (Figs 1 and 2), e.g. to propose new hypotheses and find 
answers to the biological questions of interest related to Alzheimer’s disease. However, novel machine-learning 
algorithms are needed to utilize such heterogeneous big data. Below we demonstrate how HENA can be analysed 
using graph convolutional networks, a state-of-the-art deep learning methods for large graphs23,103,104.
analysis of the heterogeneous graph using graph convolutional networks. The understanding 
of disease mechanisms on different levels is not a trivial task. Here we demonstrate an application of state-of-the 
art graph convolutional networks to identify genes that are potentially associated with Alzheimer’s disease using 
biological information about genes and interactions of different types between pairs of genes and proteins. We 
also show how additional data sets can be used together with the HENA data set.
The most straightforward way to approach this problem would be to use a supervised machine learning approach, 
where genes are labeled based on their association with Alzheimer’s disease. Using the labeled set of genes we can train 
a model to find a decision boundary between two classes, and apply it to predict the association for the rest of the genes.
Combining HENA with an additional data set. Defining a positive and negative class for the model: Despite the 
substantial number of studies that have been carried out in the field of Alzheimer’s disease research, a set of con-
firmed positive and negative associations of genes and Alzheimer’s disease is not yet well defined. The genes (and 
proteins as their products) can be defined as associated with the disease, for example, based on genome-wide asso-
ciation studies and based on domain-expert-curated knowledge. We used information about the nodes from HENA 
to assemble a set of 944 genes associated with the disease based on the GWAS data set and Alzheimer’s-related PPI 
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data set collected in HENA. Selecting a set of genes that is clearly not associated with the Alzheimer’s disease is 
even more challenging, and leads to the difficulty of defining the negative class. In this case study we approached 
this challenge by defining a negative class as a set of 1572 essential non-disease genes described in the evolutionary 
study by Spataro et al.105. The rest of the genes present in HENA are labeled as unknown.
Heterogeneous graph as an input for the model: The HENA data set can be represented as a heterogeneous 
graph, with nodes representing genes, and edges representing multiple biological relations between the genes (see 
Fig. 3). For this case study we have excluded IGRI to keep interactions between nodes that were mapped directly 
to genes, and co-expression interactions in disease related brain regions with low co-expression values (<0.5). 
Some sets of node attributes (or features) in HENA are incomplete due to the absence of the required informa-
tion in the various sources describing them. We have also excluded the feature describing gene positive selection 
since it was not present for most of the genes. Nodes in the network were labeled according to association of the 
corresponding genes to Alzheimer’s disease, i.e. positive/negative labels for those known to be associated/not 
associated with the disease, unknown for those whose association with the disease is unknown. A summary of 
the resulting graph is shown in Table 5.
Graph convolutional networks for heterogeneous graphs. Generalization of GCNs for heterogeneous graphs: 
Recent advances in network analysis demonstrate that methods based on graph convolutional networks (GCN) 
outperform other traditional methods for many classification tasks on network data106. One of the GCN-related 
approaches, the GraphSAGE model, was proposed by Hamilton et al.23. It addresses several major issues that 
other GCN approaches suffer from. The most relevant to this study is scalability — most of the methods can not 
be applied to large graphs, while GraphSAGE is scalable to graphs with billions of nodes107. The second issue is 
the ability to work in an inductive setting as opposed to a transductive one. In a nutshell, the transductive learning 
does not generalize to unseen nodes, while inductive GraphSAGE can generate node embeddings — node fea-
ture vector representations — for nodes that were not seen during the training. We apply a generalization of the 
GraphSAGE algorithm23 to heterogeneous networks — HinSAGE103. The main difference from the homogeneous 
GraphSAGE23 is that HinSAGE takes into account and creates embeddings for different edge types.
Feature generation: To determine whether network topological features can provide additional information 
for the model, we have created three sets of features — biological features, graph-related features and a combined 
set of biological and graph-related features that we refer as all features.
Biological features here represent levels of aggregated gene expression in the 231 brain region and a value, 
representing genes, expressed higher in disease-associated regions (CA1-CA4, DG, SptN, subiculum) compared 
with the rest of the brain regions. This value was obtained by the application of the Wilcoxon test108 to compare 
gene expression in disease-associated regions and the rest of the brain regions.
Graph features for each node represent a combination of graph embeddings, generated by GraphSAGE23 and 
proportions of Alzheimer’s disease-associated genes in the first and second hop neighbourhood of each node. 
In this study we use an unsupervised version of GraphSAGE, where for each node we learn embeddings, i.e. 
low-dimensional vector representations for network nodes, based on both node features and the graph structure. 
Each node is then represented via a numeric vector of a specified fixed dimension (256 in our case) that captures 
the node properties in the graph in addition to the node features. Moreover, as we deal with a heterogeneous 
graph, we learn embeddings for each of the three sub-graphs, where a subgraph consists of edges of a particular 
Fig. 5 Comparison of HENA data set with public databases. The number of intersecting interactions between 
HENA, GeneMania and STRING are demonstrated respectively in, (a) PPI, (b) co-expression and (c) genetic 
interactions. The line between the two data sets in the figure meta-data displayed under x-axes represents the 
intersecting sets. In the case of a data set intersecting with itself, a single dot is displayed.
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type, i.e. co-expression, PPI, epistasis. Therefore, the dimensionality of the resulting embedding vector for each 
node is 256 × 3 as we concatenate embeddings from sub-graphs for each edge type.
A third set of features all features consists of the combined biological features and graph-related features.
Nodes with these three sets of features are then used as an input for the classification model HinSAGE. The 
performance of the model on three different feature sets is described in Table 6.
Comparison with the classical supervised model: Next, we adopt a classical supervised strategy, where a ran-
dom forest classifier104 that is trained on the set of positive and negative genes for each of the feature sets. The 
results of both models’ performances are shown in Table 6. We then apply the models to the set of unknown cases 
and rank them according to the probability score. The higher the probability, the more likely the gene is associated 
with Alzheimer’s disease.
We have compared the results of random forest and HinSAGE model performance for biological, 
graph-related, and joined set of features. The results demonstrate that the model improves with the use of graph 
features. Random forest on biological features fails to get any information, all Alzheimer genes are classified as 
non-Alzheimer. HinSAGE on biological features uses the initially provided non-graph features, and propagates 
this information exploiting the graph structure. It demonstrates better performance than random forest on a 
set of biological features. We can notice that the performance of both models improves with the introduction of 
graph features. It is reflected by all indicated model performance metrics, i.e. precision, recall, F1, ROC AUC. 
However, due to positive and negative class imbalance, we refer to the F1 score, i.e. a harmonic average of the pre-
cision and recall of the model, as the most representative metric of model performance. Taking this into account, 
we conclude that Random Forest on graph-related feature set improves the performance, while HinSAGE on 
graph features is the best performing method.
Graph structure helps to capture complex relationships. For the exploratory analysis we selected genes suggested 
as candidates for an association with the Alzheimer’s disease by the algorithms. Here we performed surveyed the 
existing body of research about the suggested genes.
For this purpose we have created a list of genes, shown to have a strong association with the disease, from 
the recent publications. These publications include GWAS109–111 and genome-wide association study by proxy 
(GWAX) studies112, list of disease-specific autoantibodies in human sera113, list of genes reported to be associated 
in Alzheimer’s disease downloaded from the MalaCards database114, and the results of integrative transcriptome 
analysis by Raj et al.115. This combined list resulted in 169 nodes present in the result of the classification. For each 
model results we have selected genes that were assigned a probability of ≥0.5 to be associated with Alzheimer’s 
disease. Random forest classified 14 out if 169 genes to be associated with the disease while HinSAGE classified 
154 genes from the list to be associated with the disease. Interestingly, the genes ACE, ADAMTS4 and CLNK, 
recently reported in three independent GWAS meta analysis publications109–111 were classified as Alzheimer’s 
disease-related genes with the corresponding probabilities 0.81, 0.93 and 0.88 while random forest did not classify 
them as Alzheimer’s disease-related genes.
These qualitative findings of the subset of genes demonstrate that graph structure is a rich data source that 
helps to capture complex relationships and find the distinctive patterns that are not easily detectable otherwise.
The prediction of genes related to complex diseases, such as Alzheimer’s disease, is not a trivial task. The 
ambiguity in the definition of the node class, i.e. relation to the disease, and selection of the informative features 
strongly influences the model performance. However, we have demonstrated the advantage of using graph struc-
tural information in node classification task compared to using biologically determined features alone.
# Nodes # Edges
full graph 24825 9740721
PPI subgraph 10445 52003
co-expression subgraph 14634 9671535
epistasis subgraph 13881 17183
Table 5. Number of nodes and edges for each subgraph.
HinSAGE
Precision Recall F1 score ROC AUC
All 0.40 0.98 0.57 0.60
Graph 0.40 0.98 0.57 0.66
Biological 0.37 0.94 0.54 0.56
Random Forest
All 0.50 0.50 0.50 0.82
Graph 0.50 0.50 0.50 0.83
Biological 0.43 0.27 0.33 0.56
Table 6. Comparison of the model performance for different feature sets and for two models.
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Code availability
Data integration and analysis were performed using R language for statistical computing95 version 3.0.2 (2013-
05-16), R version 3.3.1 (2016-06-21), R version 3.4.2 (2017-09-18). The case study was built using Python 3.6. The 
project repository is accessible via GitHub HENA repository and accompanied by DOI116,117.
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